BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 38429415)

  • 1. Sarcoma microenvironment cell states and ecosystems are associated with prognosis and predict response to immunotherapy.
    Subramanian A; Nemat-Gorgani N; Ellis-Caleo TJ; van IJzendoorn DGP; Sears TJ; Somani A; Luca BA; Zhou MY; Bradic M; Torres IA; Oladipo E; New C; Kenney DE; Avedian RS; Steffner RJ; Binkley MS; Mohler DG; Tap WD; D'Angelo SP; van de Rijn M; Ganjoo KN; Bui NQ; Charville GW; Newman AM; Moding EJ
    Nat Cancer; 2024 Apr; 5(4):642-658. PubMed ID: 38429415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atlas of clinically distinct cell states and ecosystems across human solid tumors.
    Luca BA; Steen CB; Matusiak M; Azizi A; Varma S; Zhu C; Przybyl J; Espín-Pérez A; Diehn M; Alizadeh AA; van de Rijn M; Gentles AJ; Newman AM
    Cell; 2021 Oct; 184(21):5482-5496.e28. PubMed ID: 34597583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sarcomas: Immune biomarker expression and checkpoint inhibitor trials.
    Zhu MMT; Shenasa E; Nielsen TO
    Cancer Treat Rev; 2020 Dec; 91():102115. PubMed ID: 33130422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improving Immunotherapy Efficacy in Soft-Tissue Sarcomas: A Biomarker Driven and Histotype Tailored Review.
    Roulleaux Dugage M; Nassif EF; Italiano A; Bahleda R
    Front Immunol; 2021; 12():775761. PubMed ID: 34925348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identifying specific TLS-associated genes as potential biomarkers for predicting prognosis and evaluating the efficacy of immunotherapy in soft tissue sarcoma.
    Wang XX; Liu YP; Lu Y; Wu LH; Ren JY; Ji H; Wang X; Zhang HM
    Front Immunol; 2024; 15():1372692. PubMed ID: 38720884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The N
    Zhao R; Li B; Zhang S; He Z; Pan Z; Guo Q; Qiu W; Qi Y; Zhao S; Wang S; Chen Z; Zhang P; Guo X; Xue H; Li G
    Front Immunol; 2021; 12():653711. PubMed ID: 34354698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy for sarcomas.
    Nakata E; Fujiwara T; Kunisada T; Ito T; Takihira S; Ozaki T
    Jpn J Clin Oncol; 2021 Apr; 51(4):523-537. PubMed ID: 33611603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Facts and Hopes in Immunotherapy of Soft-Tissue Sarcomas.
    Martín-Broto J; Moura DS; Van Tine BA
    Clin Cancer Res; 2020 Nov; 26(22):5801-5808. PubMed ID: 32601077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of Prognostic lncRNA Related to the Immune Microenvironment of Soft Tissue Sarcoma.
    Dai WY; Wang B; Li JY; Luo ZP
    Biomed Res Int; 2022; 2022():9471558. PubMed ID: 35155682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The KrasG12D;Trp53fl/fl murine model of undifferentiated pleomorphic sarcoma is macrophage dense, lymphocyte poor, and resistant to immune checkpoint blockade.
    Hildebrand KM; Singla AK; McNeil R; Marritt KL; Hildebrand KN; Zemp F; Rajwani J; Itani D; Bose P; Mahoney DJ; Jirik FR; Monument MJ
    PLoS One; 2021; 16(7):e0253864. PubMed ID: 34242269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy: A New (and Old) Approach to Treatment of Soft Tissue and Bone Sarcomas.
    Nathenson MJ; Conley AP; Sausville E
    Oncologist; 2018 Jan; 23(1):71-83. PubMed ID: 28935774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An immunosuppressive macrophage profile attenuates the prognostic impact of CD20-positive B cells in human soft tissue sarcoma.
    Tsagozis P; Augsten M; Zhang Y; Li T; Hesla A; Bergh J; Haglund F; Tobin NP; Ehnman M
    Cancer Immunol Immunother; 2019 Jun; 68(6):927-936. PubMed ID: 30879106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Machine learning analysis of gene expression data reveals novel diagnostic and prognostic biomarkers and identifies therapeutic targets for soft tissue sarcomas.
    van IJzendoorn DGP; Szuhai K; Briaire-de Bruijn IH; Kostine M; Kuijjer ML; Bovée JVMG
    PLoS Comput Biol; 2019 Feb; 15(2):e1006826. PubMed ID: 30785874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genomic stratification based on microenvironment immune types and PD-L1 for tailoring therapeutic strategies in bladder cancer.
    Lyu X; Wang P; Qiao Q; Jiang Y
    BMC Cancer; 2021 May; 21(1):646. PubMed ID: 34059019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single cell analysis reveals distinct immune landscapes in transplant and primary sarcomas that determine response or resistance to immunotherapy.
    Wisdom AJ; Mowery YM; Hong CS; Himes JE; Nabet BY; Qin X; Zhang D; Chen L; Fradin H; Patel R; Bassil AM; Muise ES; King DA; Xu ES; Carpenter DJ; Kent CL; Smythe KS; Williams NT; Luo L; Ma Y; Alizadeh AA; Owzar K; Diehn M; Bradley T; Kirsch DG
    Nat Commun; 2020 Dec; 11(1):6410. PubMed ID: 33335088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Immunosuppressive Niche of Soft-Tissue Sarcomas is Sustained by Tumor-Associated Macrophages and Characterized by Intratumoral Tertiary Lymphoid Structures.
    Chen L; Oke T; Siegel N; Cojocaru G; Tam AJ; Blosser RL; Swailes J; Ligon JA; Lebid A; Morris C; Levin A; Rhee DS; Johnston FM; Greer JB; Meyer CF; Ladle BH; Thompson ED; Montgomery EA; Choi W; McConkey DJ; Anders RA; Pardoll DM; Llosa NJ
    Clin Cancer Res; 2020 Aug; 26(15):4018-4030. PubMed ID: 32332015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of Exosome-Related Gene Risk Model to Evaluate the Tumor Immune Microenvironment and Predict Prognosis in Triple-Negative Breast Cancer.
    Qiu P; Guo Q; Yao Q; Chen J; Lin J
    Front Immunol; 2021; 12():736030. PubMed ID: 34659224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of the m6A-Associated Tumor Immune Microenvironment in Prostate Cancer to Aid Immunotherapy.
    Liu Z; Zhong J; Zeng J; Duan X; Lu J; Sun X; Liu Q; Liang Y; Lin Z; Zhong W; Wu W; Cai C; Zeng G
    Front Immunol; 2021; 12():735170. PubMed ID: 34531875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-cell transcriptome analysis revealed a suppressive tumor immune microenvironment in EGFR mutant lung adenocarcinoma.
    Yang L; He YT; Dong S; Wei XW; Chen ZH; Zhang B; Chen WD; Yang XR; Wang F; Shang XM; Zhong WZ; Wu YL; Zhou Q
    J Immunother Cancer; 2022 Jan; 10(2):. PubMed ID: 35140113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging Targeted and Immune-Based Therapies in Sarcoma.
    Pollack SM; Ingham M; Spraker MB; Schwartz GK
    J Clin Oncol; 2018 Jan; 36(2):125-135. PubMed ID: 29220291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.